Listed pet care firms post modest gains as sector stays resilient

Listed pet care firms are still producing positive returns, but not by much. GlobalPETS reported that the Global Pet Care Index delivered a 3.16% gross return over the past 12 months, framing the sector as resilient even as companies contend with market swings and higher operating costs, including pressure linked to oil prices. The broader read-through from recent market coverage is similar: pet care remains relatively steady, but it’s no longer the standout growth story it was during the pandemic-era boom. (globalpetindustry.com)

That moderation has been building for some time. Industry analyses from Cascadia Capital, as cited by PetfoodIndustry, show publicly traded pet companies still posting revenue growth in 2025, but with stock performance generally trailing the S&P 500 as growth and earnings normalized. Separate reporting has also pointed to a more bifurcated market, where retailers have held up better than some food and animal health names, and where premiumization continues, but with more visible consumer trade-offs underneath. (petfoodindustry.com)

One company-level example is H&H Group. GlobalPETS reported that its Pet Nutrition and Care business grew 8.7% to RMB 2.5 billion in FY2025, with Zesty Paws doing much of the work on the top line, while profitability margins declined. H&H’s own 2025 outlook disclosures said the pet segment achieved a high single-digit revenue increase on a comparable basis, and an earnings-call transcript published by Investing.com said the segment’s 2025 EBITDA margin was 3.1%, with management pointing to Zesty Paws and investment in expansion markets, alongside tariff-related pressure on profitability. The company has also signaled continued international expansion for Zesty Paws, including Europe, the UK, and Asia. (itiger.com)

The backdrop helps explain why “resilient” and “modest” are showing up in the same conversation. Reporting across the pet food and pet business trade press has described an industry that is still benefiting from long-term demand drivers, but facing inflation, demographic shifts, and a more cautious consumer environment. In that setting, companies with exposure to supplements, preventive wellness, and higher-margin premium products appear better positioned than those relying more heavily on discretionary categories alone. That’s an inference from the pattern in recent earnings and sector reporting, rather than a single stated conclusion, but it’s a consistent one. (petfoodindustry.com)

Expert and industry commentary has reinforced that view. S&P Global analysts, quoted by GlobalPETS in separate coverage of pet-sector credit ratings, highlighted debt reduction and new product launches as positives for Elanco, while the same report noted stress elsewhere in the sector, including downgrades tied to veterinary practice management and distribution businesses. Investors quoted in GlobalPETS’ recent funding coverage also suggested that capital may be more available in 2026 than it was in 2025, but that selectivity remains high. In other words, the market still sees pet care as attractive, though not indiscriminately so. (globalpetindustry.com)

Why it matters: For veterinary professionals, this kind of market signal matters because public-company performance often shapes what happens downstream in product development, channel strategy, and commercial partnerships. If listed pet care companies are growing, but only modestly rewarding investors, management teams may stay focused on margin discipline, premium mix, and categories with recurring demand, such as supplements, therapeutic nutrition, diagnostics, and preventive care. That can affect how manufacturers support clinics, how aggressively brands compete for veterinary recommendation, and how pet parents respond to pricing across food, wellness, and care. The resilience is encouraging, but it also suggests a more selective, cost-conscious phase for the industry. (petfoodindustry.com)

What to watch: The next signals will likely come from 2026 earnings updates, margin commentary, and any evidence that input-cost pressure is easing. It will also be worth watching whether supplements-led growth at companies like H&H can translate into stronger profitability, and whether the broader sector can close the gap between steady operating performance and still-muted shareholder returns. (itiger.com)